NewLink Genetics Corp. (NASDAQ:NLNK) shares were up 3.1% on Friday . The stock traded as high as $11.26 and last traded at $11.23, with a volume of 98,382 shares trading hands. The stock had previously closed at $10.89.

Several research analysts have weighed in on NLNK shares. Stifel Nicolaus dropped their price objective on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Mizuho dropped their price objective on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 target price on shares of NewLink Genetics Corp. in a research report on Friday, April 29th. Zacks Investment Research downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, SunTrust Banks Inc. downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $59.00 to $12.00 in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $23.29.

The stock has a 50 day moving average of $11.10 and a 200-day moving average of $17.35. The stock’s market capitalization is $318.34 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings data on Friday, April 29th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $0.88. The firm had revenue of $4.34 million for the quarter, compared to the consensus estimate of $2.08 million. On average, analysts anticipate that NewLink Genetics Corp. will post ($2.62) earnings per share for the current year.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. EQIS Capital Management raised its position in NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares during the last quarter. GSA Capital Partners LLP raised its position in NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares during the last quarter. California State Teachers Retirement System raised its position in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock valued at $1,765,000 after buying an additional 300 shares during the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.